Tapering long-term opioid therapy is an increasingly common practice, yet rapid opioid dose reductions may increase the risk of overdose. The objective of this study was to compare overdose risk following opioid dose reduction rates of ≤10%, 11% to 20%, 21% to 30%, and >30% per month to stable dosing.
Methods:
We conducted a retrospective cohort study in three health systems in Colorado and Wisconsin. Participants were patients ≥18 years of age prescribed long-term opioid therapy between January 1, 2006, and June 30, 2019. Five opioid dosing patterns and drug overdoses (fatal and nonfatal) were identified using electronic health records, pharmacy records, and the National Death Index. Cox proportional hazard regression was conducted on a propensity score-weighted cohort to estimate adjusted hazard ratios (aHRs) for follow-up periods of 1, 3, 6, 9, and 12 months after a dose reduction.
Results:
In a cohort of 17 540 patients receiving long-term opioid therapy, 42.7% of patients experienced a dose reduction. Relative to stable dosing, a dose reduction rate of >30% was associated with an increased risk of overdose and the aHR estimates decreased as the follow-up increased; the aHRs for the 1-, 6- and 12-month follow-ups were 5.33 (95% CI, 1.98-14.34), 1.81 (95% CI,1.08-3.03), and 1.49 (95% CI, 0.97-2.27), respectively. The slower tapering rates were not associated with overdose risk.
Conclusions:
Patients receiving long-term opioid therapy exposed to dose reduction rates of >30% per month had increased overdose risk relative to patients exposed to stable dosing. Results support the use of slow dose reductions to minimize the risk of overdose.
DowellDHaegerichTMChouR.CDC Guideline for prescribing opioids for chronic pain - United States, 2016. MMWR Recomm Rep. 2016;65(1):1-49.
2.
DowellDRaganKRJonesCMBaldwinGTChouR.CDC Clinical practice guideline for prescribing opioids for pain - United States, 2022. MMWR Recomm Rep. 2022;71(3):1-95.
DowellDHaegerichTChouR.No shortcuts to safer opioid prescribing. N Engl J Med. 2019;380(24):2285-2287.
6.
BinswangerIAGlanzJMFaulM, et al. The association between opioid discontinuation and heroin use: a nested case-control study. Drug Alcohol Depend. 2020;217:108248.
7.
DarnallBDJuurlinkDKernsRD, et al. International stakeholder community of pain experts and leaders call for an urgent action on forced opioid tapering. Pain Med. 2019;20(3):429-433.
8.
KroenkeKAlfordDPArgoffC, et al. Challenges with implementing the Centers for Disease Control and Prevention opioid guideline: a consensus panel report. Pain Med. 2019;20(4):724-735.
9.
MackeyKAndersonJBourneDChenEPetersonK.Evidence brief: benefits and harms of long-term opioid dose reduction or discontinuation in patients with chronic pain. VA Evidence-based Synthesis Program Reports; 2019.
10.
OlivaEMBoweTManhapraA, et al. Associations between stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: observational evaluation. BMJ. 2020;368:m283.
11.
KerteszSGManhapraA.The drive to taper opioids: mind the evidence, and the ethics. Spinal Cord Ser Cases. 2018;4:64.
AgnoliAXingGTancrediDJMagnanEJerantAFentonJJ.Association of dose tapering with overdose or mental health crisis among patients prescribed long-term opioids. JAMA. 2021;326(5):411-419.
14.
DiPreteBLRanapurwalaSIMaierhoferCN, et al. Association of opioid dose reduction with opioid overdose and opioid use disorder among patients receiving high-dose, long-term opioid therapy in North Carolina. JAMA Netw Open. 2022;5(4):e229191.
15.
FrankJWLevyCMatlockDD, et al. Patients’ perspectives on tapering of chronic opioid therapy: a qualitative study. Pain Med. 2016;17(10):1838-1847.
16.
SturgeonJASullivanMDParker-ShamesSTaubenDCoelhoP.Outcomes in long-term opioid tapering and buprenorphine transition: a retrospective clinical data analysis. Pain Med. 2020;21(12):3635-3644.
17.
EverittBS.The Cambridge Dictionary of Statistics. Cambridge University Press; 1998.
18.
GlazJPozdnyakovVWallensteinS, eds. Scan Statistics: Methods and Applications. Springer Science + Business Media; 2009.
19.
NausJI.The distribution of the size of the maximum cluster of points on a line. J Am Stat Assoc. 1965;60(310):532-538.
20.
RossTRNgDBrownJS, et al. The HMO research network virtual data warehouse: a public data model to support collaboration. EGEMS. 2014;2(1):1049.
Von KorffMSaundersKThomas RayG, et al. De facto long-term opioid therapy for noncancer pain. Clin J Pain. 2008;24(6):521-527.
23.
DunnKMSaundersKWRutterCM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010;152(2):85-92.
24.
GlanzJMBinswangerIAShetterlySMNarwaneyKJXuS.Association between opioid dose variability and opioid overdose among adults prescribed long-term opioid therapy. JAMA Netw Open. 2019;2(4):e192613.
25.
GlanzJMNarwaneyKJMuellerSR, et al. Prediction model for two-year risk of opioid overdose among patients prescribed chronic opioid therapy. J Gen Intern Med. 2018;33(10):1646-1653.
26.
BinswangerIAShetterlySMXuS, et al. Opioid dose trajectories and associations with mortality, opioid use disorder, continued opioid therapy, and health plan disenrollment. JAMA Netw Open. 2022;5(10):e2234671.
27.
American Society of Addiction Medicine. The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. J Addict Med. 2020;14(2S Suppl 1):1-91.
28.
Substance Abuse and Mental Health Services Administration. Medications for Opioid Use Disorder - For Healthcare and Addiction Professionals, Policymakers, Patients, and Families. TIP 63.: U.S. Department of Health and Human Services; 2021.
29.
NagarwallaN.A scan statistic with a variable window. Stat Med. 1996;15(7-9):845-850.
30.
XuSHambidgeSJMcClureDLDaleyMFGlanzJM.A scan statistic for identifying optimal risk windows in vaccine safety studies using self-controlled case series design. Stat Med. 2013;32(19):3290-3299.
31.
KoHKimHKChungC, et al. Association between medication adherence and intrapatient variability in tacrolimus concentration among stable kidney transplant recipients. Sci Rep. 2021;11(1):5397.
32.
LeinoADKingECJiangW, et al. Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: establishing baseline values. Am J Transplant. 2019;19(5):1410-1420.
33.
NatarajNStrahanAEGuyGPJr.LosbyJLDowellD.Dose tapering, increases, and discontinuity among patients on long-term high-dose opioid therapy in the United States, 2017-2019. Drug Alcohol Depend. 2022;234:109392.
34.
LyuHYoshidaKZhaoSS, et al. Delayed denosumab injections and fracture risk among patients with osteoporosis: a population-based cohort study. Ann Intern Med. 2020;173(7):516-526.
35.
BinswangerIANarwaneyKJGardnerEMGabellaBACalcaterraSLGlanzJM.Development and evaluation of a standardized research definition for opioid overdose outcomes. Subst Abus. 2019;40(1):71-79.
36.
Centers for Disease Control and Prevention. Prescription drug overdose data & statistics - guide to ICD-9-CM and ICD-10 codes related to poisoning and pain. 2013. Accessed May 24, 2023. https://stacks.cdc.gov/view/cdc/59394
37.
DeyoRACherkinDCCiolMA.Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
38.
QuanHSundararajanVHalfonP, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130-1139.
39.
LiFLiF.Propensity score weighting for causal inference with multiple treatments. Ann Appl Stat. 2019;13(4):2389-2415.
40.
AustinPC.Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083-3107.
41.
VanderWeeleTJDingP.Sensitivity analysis in observational research: Introducing the e-value. Ann Intern Med. 2017;167(4):268-274.
42.
HallvikSEEl IbrahimiSJohnstonK, et al. Patient outcomes after opioid dose reduction among patients with chronic opioid therapy. Pain. 2022;163(1):83-90.
43.
MuellerSRGlanzJMNguyenAP, et al. Restrictive opioid prescribing policies and evolving risk environments: a qualitative study of the perspectives of patients who experienced an accidental opioid overdose. Int J Drug Policy. 2021;92:103077.
44.
KosakowskiSBenintendiALagisettyPLarochelleMRBohnertASBBazziAR.Patient perspectives on improving patient-provider relationships and provider communication during opioid tapering. J Gen Intern Med. 2022;37(7):1722-1728.
45.
FentonJJMagnanETseregounisIEXingGAgnoliALTancrediDJ.Long-term risk of overdose or mental health crisis after opioid dose tapering. JAMA Netw Open. 2022;5(6):e2216726.
46.
MarkTLParishW.Opioid medication discontinuation and risk of adverse opioid-related health care events. J Subst Abuse Treat. 2019;103:58-63.
47.
QuinnPDChangZBairMJ, et al. Associations of opioid prescription dose and discontinuation with risk of substance-related morbidity in long-term opioid therapy. Pain. 2022;163(4):e588-e595.
48.
KarmaliRNBushCRamanSRCampbellCISkinnerACRobertsAW.Long-term opioid therapy definitions and predictors: a systematic review. Pharmacoepidemiol Drug Saf. 2020;29(3):252-269.
49.
de Oliveira CostaJBrunoCBaranwalN, et al. Variations in long-term opioid therapy definitions: a systematic review of observational studies using routinely collected data (2000-2019). Br J Clin Pharmacol. 2021;87(10):3706-3720.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
